Efficacy and Safety of Neoadjuvant Treatment with Bevacizumab, Liposomal Doxorubicin, Cyclophosphamide and Paclitaxel Combination in Locally/Regionally Advanced, HER2-Negative, Grade III at Premenopausal Status Breast Cancer: A Phase II Study
Titel:
Efficacy and Safety of Neoadjuvant Treatment with Bevacizumab, Liposomal Doxorubicin, Cyclophosphamide and Paclitaxel Combination in Locally/Regionally Advanced, HER2-Negative, Grade III at Premenopausal Status Breast Cancer: A Phase II Study
Auteur:
Tampaki, Ekaterini C. Tampakis, Athanasios Alifieris, Constantinos E. Krikelis, Dimitrios Pazaiti, Anastasia Kontos, Michalis Trafalis, Dimitrios T.